IL31 and Alzheimer disease: The course of AD is characterized by biphasic inflammation, the Th2 and Th22 inflammatory pathways predominate at the onset and in the acute phases of disease, with an increase in tissue and serum levels of several cytokines, including IL4, IL5, IL13, IL22, IL31, and TSLP [26,27].